Search

Your search keyword '"Gianenrico Senna"' showing total 351 results

Search Constraints

Start Over You searched for: Author "Gianenrico Senna" Remove constraint Author: "Gianenrico Senna"
351 results on '"Gianenrico Senna"'

Search Results

1. Eosinophilic esophagitis and inhalant antigens: Pointing out the roles of allergic rhinitis, immunotherapy and biologic treatment

2. Asthma severity: the patient’s point of view

3. Idiopathic hypereosinophilic syndromes and rare dysimmune conditions associated with hyper-eosinophilia in practice: An innovative multidisciplinary approach

4. Profiling severe asthma: Any relevance for age? An analysis from Severe Asthma Network Italy (SANI) cohort

5. Tezepelumab: patient selection and place in therapy in severe asthma

6. Updated grading system for systemic allergic reactions: Joint Statement of the World Allergy Organization Anaphylaxis Committee and Allergen Immunotherapy Committee

7. Low-dose anti-IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance

8. Managing Patients with Hypereosinophilic Syndrome: A Statement from the Italian Society of Allergy, Asthma, and Clinical Immunology (SIAAIC)

9. Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study

10. Evaluation of Clinical Remission in Best-Performing Severe Asthmatic Patients Treated for Three Years with Mepolizumab

11. Global disparities in availability of epinephrine auto-injectors

12. Relationship between hair shedding and systemic inflammation in COVID-19 pneumonia

13. Dupilumab Efficacy on Asthma Functional, Inflammatory, and Patient-Reported Outcomes across Different Disease Phenotypes and Severity: A Real-Life Perspective

14. Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life

15. ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study

16. The intriguing possibility of using probiotics in allergen-specific immunotherapy

17. The potential protective role of corticosteroid therapy in patients with asthma and COPD against COVID-19

18. Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders

19. Air Pollution and microRNAs: The Role of Association in Airway Inflammation

20. Clinical response to biologicals for severe asthma: any relevance for sex in different age ranges?

21. Relative Humidity and Its Impact on the Immune System and Infections

22. Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis

23. Introduction of the telemonitoring device Turbo+ in the management of patients suffering from asthma in Italy: a budget impact analysis

24. Physicians’ prescribing behaviour and clinical practice patterns for allergic rhinitis management in Italy

25. Oral health in asthmatic patients: a review

26. Urticaria: recommendations from the Italian Society of Allergology, Asthma and Clinical Immunology and the Italian Society of Allergological, Occupational and Environmental Dermatology

27. Upsides and downsides of a telecounselling model of integrated asthma management between general practitioners and specialists

28. TSLP and HMGB1: Inflammatory Targets and Potential Biomarkers for Precision Medicine in Asthma and COPD

29. Severe asthma: One disease and multiple definitions

30. ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments

31. IL-33 and the Cytokine Storm in COVID-19: From a Potential Immunological Relationship towards Precision Medicine

32. Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life

33. COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee

34. Allergy and coronavirus disease (COVID-19) international survey: Real-life data from the allergy community during the pandemic

35. World allergy organization anaphylaxis guidance 2020

36. Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

40. Minimal clinically important difference for asthma endpoints: an expert consensus report

42. The control of allergic rhinitis in real life: a multicenter cross-sectional Italian study

43. Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies

44. COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control

45. Asthma control in primary care: the results of an observational cross-sectional study in Italy and Spain

46. Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry

47. Trends and determinants of Emergency Room admissions for asthma: A retrospective evaluation in Northeast Italy

48. Importance of Cardiopulmonary Exercise Testing amongst Subjects Recovering from COVID-19

49. Who Is Really at Risk for Anaphylaxis Due to COVID-19 Vaccine?

50. Fatal asthma; is it still an epidemic?

Catalog

Books, media, physical & digital resources